Prosecution Insights
Last updated: October 27, 2026
Application No. 18/581,509

SOLID MEDICATION DISPENSING DEVICE

Final Rejection §112
Filed
Feb 20, 2024
Priority
Nov 13, 2023 — provisional 63/598,352
Examiner
RANDALL, JR., KELVIN L
Art Unit
3651
Tech Center
3600 — Transportation & Electronic Commerce
Assignee
Imam Abdulrahman Bin Faisal University
OA Round
2 (Final)
45%
Grant Probability
Moderate
3-4
OA Rounds
5m
Est. Remaining
62%
With Interview

Examiner Intelligence

Grants 45% of resolved cases
45%
Career Allowance Rate
388 granted / 864 resolved
-7.1% vs TC avg
Strong +17% interview lift
Without
With
+16.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
34 currently pending
Career history
924
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
58.4%
+18.4% vs TC avg
§102
14.3%
-25.7% vs TC avg
§112
25.5%
-14.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 864 resolved cases

Office Action

§112
DETAILED ACTION Response to Arguments Applicant’s arguments with respect to the claim(s) have been considered but are moot in view of the new ground(s) of rejections. Drawings The drawings are objected to because they include members 131 and 141 which do not appear to be shown in previous drawings. The specification describes 131 and 141 as motors but there does not appear to be any description of the structure of the motors. Adding a specific structure motor to the drawings would include new matter. Examiner invites Applicant to show where the support for the structures of 131 and 141 is located. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Objections Claims 10-12 are objected to because of the following informalities: Claim 10 recites “receive a receive a”. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 2, and 5-20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 recites “and to control an orientation of the dispensing distributor to direct the portion of the solid medication”, Examiner notes that it is unclear as to what is controlling the orientation of the dispensing distributor. Examiner believes the claim should recite “the controller further controlling an orientation of the dispensing distributor to direct the portion of the solid medication”. Allowable Subject Matter Claims 1, 2, and 5-20 would be allowable if rewritten or amended to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KELVIN L RANDALL, JR. whose telephone number is (571)270-5373. The examiner can normally be reached M-F: 9:00 am-5 pm est. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Gene Crawford can be reached at 571-272-6911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /K.L.R/Examiner, Art Unit 3651 /GENE O CRAWFORD/Supervisory Patent Examiner, Art Unit 3651
Read full office action

Prosecution Timeline

Feb 20, 2024
Application Filed
Apr 08, 2026
Non-Final Rejection mailed — §112
Jul 01, 2026
Applicant Interview (Telephonic)
Jul 11, 2026
Examiner Interview Summary
Jul 17, 2026
Response Filed
Oct 07, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12759754
USER-ASSEMBLED DISPENSER
4y 3m to grant Granted Oct 13, 2026
Patent 12738121
SELF-CONTAINED AND DEMAND-ADAPTABLE WARMER FOR STORING, HEATING, AND HOLDING READY-TO-DRINK BEVERAGES
3y 10m to grant Granted Sep 15, 2026
Patent 12735244
Waste Bag Gauge
2y 7m to grant Granted Sep 15, 2026
Patent 12734112
Automatic, Gravity-Fed, Solid Dosage Form Dispenser
2y 2m to grant Granted Sep 15, 2026
Patent 12703572
PHARMACEUTICAL ORDER PROCESSING SYSTEMS AND METHODS
5y 2m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
45%
Grant Probability
62%
With Interview (+16.7%)
3y 1m (~5m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 864 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month